Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which works best for high potassium? new study tests three emergency options

NCT ID NCT04012138

Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared three emergency treatments for dangerously high potassium levels: insulin with dextrose, nebulized salbutamol, or a combination of both. Researchers measured how well each lowered potassium within 60 minutes. The trial involved 419 adults in emergency departments to find the safest and most effective approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Salbutamol and insulin aspart
What this could lead to
If successful, this trial could identify the most effective first-line treatment for acute hyperkalemia, improving emergency care and reducing complications.
What could go wrong
This is a completed Phase 4 trial, but results may not apply to all patient groups. The treatments have known side effects like low blood sugar or rapid heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

419 people

The number who actually took part.

Started

Dec 2019

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient older than 18 years old * Patient admitted to the emergency department, * Patient with local laboratory serum potassium level superior or equal to 5,5 mmol/l, * Patient who provide written informed consent prior to participation in the study Exclusion Criteria: * Hemolysis or thrombocytosis \> 106/mm3 or hyperleukocytosis \> 105/mm3 on the first blood sample suspecting a pseudohyperkalemia, * Diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome, * Pregnant or lactating woman, women with childbearing potential who didn't have effective contraception\*, * Patient expected to require emergency intubation and ventilation, * Patient expected to require dialysis, diuretics or bicarbonate within the first 60 minutes, * Patient with heart rhythm disorders or high grade atrioventricular bloc who require urgent medication as soon as admission or serum potassium level result, * Hypersensitivity to the tested active substance or excipients, * Acute coronary syndrome, * Patient not affiliated to a health insurance plan, * Patient under guardianship, curatorship or safeguard of justice. * The contraceptives considered as highly effective and acceptable by CTFG recommendations will be considered effective under this protocol. The list of contraceptives considered as highly effective and acceptable by CTFG recommendations is detailed in Appendix 7

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperkalemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperkalemia Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperkalemia

Contacts and locations

Locations

  • Agen Hospital

    Agen, France

  • Angers University Hospital

    Angers, France

  • Avicenne University Hospital

    Bobigny, France

  • La Pitié Salpêtrière University Hospital

    Paris, France

  • Lariboisiere Hospital

    Paris, France

  • Louis Mourier Hospital

    Colombes, France

  • Nancy University Hospital

    Nancy, France

  • Nantes University Hospital

    Nantes, France

  • Nice University Hospital

    Nice, France

  • Poitiers University Hospital

    Poitiers, France

  • Rennes University Hospital

    Rennes, France

  • Saint Antoine University Hospital

    Paris, France

  • Strasbourg University Hospital

    Strasbourg, France

  • Tours University Hospital

    Tours, France

  • University Hospital, Clermont-Ferrand

    Clermont-Ferrand, France

  • University Hospital, Grenoble

    Grenoble, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.